New NPY research & Panion in Feminvest event 6 March in Malmö

Panion’s CEO Anja Holm will present the company’s plans, progress and outlook at the Feminvest investors event in Malmö on the 6.th of March 2018, 17.00 – 20.30. New as well as existing shareholders can ask questions and satisfy their interest in the company’s potential. http://www.feminvest.nu

“I look forward to the event”, says Anja Holm, “where I will also tell a bit more about the supportive new study from Australia, which was recently published.” This study is independent of Panion’s and CombiGene’s research, but it uses the same neuropeptide NPY as a treatment in a rat model of chronic and generalized epilepsy. The study shows reduced number and duration of the seizures in the rats and increases the knowledge about NPY’s effect in different brain regions. While one must be cautious in translating this into canine epilepsy, it does indicate that NPY has a broader therapeutic potential in gene therapy.

The study can be found here:

https://www.ncbi.nlm.nih.gov/pubmed/29414380?dopt=Abstract

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.